Samsung Pharm (001360) — Cash Flow-to-Debt Ratio
Samsung Pharm (001360) has a Cash Flow-to-Debt Ratio of -0.05x as of September 2025, meaning its operating cash flow of ₩-2.29 Billion could theoretically repay 0% of its total liabilities (₩44.04 Billion) in one year. See Samsung Pharm (001360) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Samsung Pharm Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Samsung Pharm across 12 annual periods. Also explore Samsung Pharm equity growth rate to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Samsung Pharm (2012–2024)
Year-by-year debt coverage analysis for Samsung Pharm. For market capitalisation and broader financial context, see market value of Samsung Pharm.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.77x | ₩-17.30 Billion | ₩22.60 Billion | ▲ +56.0% |
| 2023 | -1.74x | ₩-27.66 Billion | ₩15.89 Billion | ▼ -1293.0% |
| 2022 | -0.12x | ₩-1.91 Billion | ₩15.32 Billion | ▲ +68.3% |
| 2021 | -0.39x | ₩-7.16 Billion | ₩18.19 Billion | ▼ -776.4% |
| 2020 | -0.04x | ₩-2.55 Billion | ₩56.81 Billion | ▲ +52.5% |
| 2019 | -0.09x | ₩-2.43 Billion | ₩25.70 Billion | ▲ +57.9% |
| 2018 | -0.22x | ₩-6.52 Billion | ₩28.98 Billion | ▼ -363.4% |
| 2017 | 0.09x | ₩5.15 Billion | ₩60.33 Billion | ▲ +148.0% |
| 2016 | -0.18x | ₩-9.94 Billion | ₩55.91 Billion | ▼ -255.1% |
| 2015 | -0.05x | ₩-4.20 Billion | ₩83.98 Billion | ▲ +87.4% |
| 2014 | -0.40x | ₩-13.58 Billion | ₩34.12 Billion | ▼ -144.4% |
| 2012 | -0.16x | ₩-11.13 Billion | ₩68.31 Billion | — |